Cigna Investments Inc. New purchased a new position in shares of TriMas Corp (NASDAQ:TRS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,921 shares of the industrial products company’s stock, valued at approximately $212,000.
A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in TriMas by 2.9% during the second quarter. Vanguard Group Inc. now owns 3,753,870 shares of the industrial products company’s stock worth $78,268,000 after buying an additional 106,133 shares in the last quarter. Fiduciary Management Inc. WI grew its position in TriMas by 4.9% during the third quarter. Fiduciary Management Inc. WI now owns 2,879,901 shares of the industrial products company’s stock worth $77,757,000 after buying an additional 134,255 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in TriMas during the third quarter worth approximately $42,807,000. State Street Corp grew its position in TriMas by 6.7% during the second quarter. State Street Corp now owns 904,136 shares of the industrial products company’s stock worth $18,849,000 after buying an additional 56,764 shares in the last quarter. Finally, Royce & Associates LP grew its position in TriMas by 14.8% during the third quarter. Royce & Associates LP now owns 596,572 shares of the industrial products company’s stock worth $16,107,000 after buying an additional 77,000 shares in the last quarter. 97.32% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Paul Swart sold 1,500 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $26.57, for a total value of $39,855.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joshua A. Sherbin sold 13,828 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $25.50, for a total value of $352,614.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,944 shares of company stock worth $486,796. Company insiders own 1.40% of the company’s stock.
Shares of TriMas Corp (NASDAQ TRS) opened at $26.60 on Thursday. The firm has a market capitalization of $1,220.00, a price-to-earnings ratio of -36.94, a price-to-earnings-growth ratio of 3.41 and a beta of 2.05. TriMas Corp has a twelve month low of $19.75 and a twelve month high of $28.85. The company has a quick ratio of 1.33, a current ratio of 2.67 and a debt-to-equity ratio of 0.62.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.com-unik.info/2018/02/01/cigna-investments-inc-new-purchases-new-stake-in-trimas-corp-trs.html.
TriMas Corporation is a designer, manufacturer and distributor of engineered products for commercial, industrial and consumer markets. The Company operates through four segments: Packaging, Aerospace, Energy and Engineered Components. The Packaging segment is a designer, manufacturer and distributor of engineered closure and dispensing systems for a range of end markets, including steel and plastic industrial, and consumer packaging applications.
Want to see what other hedge funds are holding TRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TriMas Corp (NASDAQ:TRS).
Receive News & Ratings for TriMas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriMas and related companies with MarketBeat.com's FREE daily email newsletter.